Major depressive disorder (MDD) is a highly debilitating condition that leads to a decline in daily functioning and a decrease in overall life satisfaction (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 2000). The utilization of neurofeedback for treating depression is grounded in extensive EEG research, which suggests that the left frontal area is closely linked to positive emotions, whereas the right frontal area is more involved in negative emotions (Davidson, 2004). To enhance depressive symptoms, asymmetric neurofeedback training is employed.
In the study below, the effectiveness of neurofeedback in treating individuals with treatment-resistant major depressive disorder (TRD) was examined. A total of 20 TRD patients were randomly assigned to either the neurofeedback group or the control group. The neurofeedback group underwent 20 sessions of neurofeedback, while the control group received 20 sessions of sham neurofeedback.
The primary objective of the study was to assess the change in depressive symptoms using the Hamilton Rating Scale for Depression (HAM-D). Secondary measures included changes in scores on the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and quality of life (QOL). Read about Neurofeedback and Anxiety.
The findings revealed that the neurofeedback group exhibited significant reductions in HAM-D, BDI, and BAI scores compared to the control group. Additionally, the neurofeedback group demonstrated noteworthy improvements in QOL scores compared to the control group.
Based on these results, the study concludes that neurofeedback shows promise as a novel treatment for TRD. Furthermore, the study established that neurofeedback is a safe and well-tolerated therapeutic approach.
Citations:
